HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) All Versions of this Article: adc.2007.125468v1 93/5/398    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in ADC Online Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Google Scholar Articles by Senthilnathan, S Articles by Bishop, N J PubMed PubMed Citation Articles by Senthilnathan, S Articles by Bishop, N J

Two doses of pamidronate in infants with osteogenesis imperfecta

¹ University of Sheffield, Western Bank, Sheffield, UK
² Sheffield Children’s NHS Foundation Trust, Western Bank, Sheffield, UK

Correspondence to:
Nick Bishop, Sheffield Children’s Hospital, Western Bank, Sheffield S10 2TH, UK; n.j.bishop{at}sheffield.ac.uk

Introduction: Current regimens of intravenous pamidronate for infants and children with osteogenesis imperfecta (OI) typically deliver 3–12 mg/kg/year of drug. We wished to ascertain the effect of pamidronate at 6 or 12 mg/kg/year on skeletal health in infants with OI.

Methods: We recruited 12 infants over a period of 4 years. Infants received either 6 or 12 mg/kg/year of pamidronate. Bone outcomes were assessed by skeletal surveys and DXA bone density measurements at baseline and at 12 months.

Results: Bone mass increased in both groups. Infants receiving 12 as opposed to 6 mg/kg/year pamidronate had increased spine bone density after adjusting for covariates at study entry (p = 0.04). Crush fractures improved or remained unchanged in all but one infant. Biochemical markers of bone turnover fell but remained within or above the normal range for age. Metaphyseal remodelling was not impaired.

Conclusions: Pamidronate dose in infants may influence lumbar spine bone acquisition. Pamidronate improved vertebral size after prior crush fracturing and did not over-suppress bone turnover.